Clinical Trials · NCT05352815

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

Name: A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Semaglutide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Novo Nordisk A/S
Enrollment: 1,291
Start date: Jun 2022
Locations: 281 sites, 22 countries
Primary endpoint: Change in Glycated Haemoglobin (HbA1c)

View Semaglutide compound reference